Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis

Infection and Immunity

Volumn 65, Issue 5, 1997, Pages 1800-1807

  Savoy, Anne C ^a   Lupan, David M ^a   Manalo, Pacita B ^a   Roberts, Joan S ^a   Schlageter, Annette M ^a   Weinhold, Leanne C ^a   Kozel, Thomas R ^a,b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CHLORPHENIRAMINE; CHLORPROMAZINE; CLODRONIC ACID; DEXAMETHASONE; LIPOSOME; POLYSACCHARIDE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; COLLAPSE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DEATH; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; LETHARGY; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SYMPTOMATOLOGY; YEAST;

EID: 0030901446     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.5.1800-1807.1997     Document Type: Article

References (63)

1. Barnes, C. D., and J. C. Strahlendorf. 1982. Pharmacological action and drug dosage, p. 271-312. In H. L. Foster, J. D. Small, and J. G. Fox (ed.), The mouse in biomedical research. Academic Press, Inc., New York, N.Y.
2. Beutler, B., L. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871.
3. Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34:19-30.
4. Blackstock, R., J. M. McCormack, and N. K. Hall. 1987. Induction of a macrophage-suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance. Infect. Immun. 55:233-239.
5. Blackstock, R., M. Zembala, and G. L. Asherson. 1991. Functional equivalence of cryptococcal and haptene-specific T suppressor factor (TsF). I. Picryl and oxazolone-specific TsF, which inhibit transfer of contact sensitivity, also inhibit phagocytosis by a subset of macrophages. Cell. Immunol. 136:435-447.
6. Bleeker, W. K., J. Agterberg, G. Rigter, N. van Rooijen, and J. C. Bakker. 1989. Key role of macrophages in hypotensive side effects of immunoglobulin preparations: studies in an animal model. Clin. Exp. Immunol. 77:338-344.
7. Brown, E. J., S. W. Hosea, and M. M. Frank. 1981. The role of complement in the localization of pneumococci in the splanchnic reticuloendothelial system during experimental bacteremia. J. Immunol. 126:2230-2235.
8. Bulmer, G. S., and M. D. Sans. 1967. Cryptococcus neoformuns. II. Phagocytosis by human leukocytes. J. Bacteriol. 94:1480-1483.
9. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T. R. Kozel, and L. Pirofski. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864-3872.
10. Casals-Stenzel, J., and H. O. Heuer. 1990. Use of WEB 2986 and WEB 2170 as platelet activating factor antagonists. Methods Enzymol. 187:455-465.
11. Cerami, A. 1992. Inflammatory cytokines. Clin. Immunol. Immunopathol. 62:S3-S10.
12. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neofonnans. Infect. Immun. 59:59-64.
13. Cherniak, R., E. Reiss, and S. H. Turner. 1982. A galactoxylomannan antigen of Cryptococcits neofonnans serotype A. Carbohydr. Res. 103:239-250.
14. Cochrane, C. G., H. J. Müller-Eberhard, and B. S. Aikin. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologie reactions. J. Immunol. 105:55-69.
15. De Boer, T. P., G. J. Wolbink, L. G. Thijs, J. W. Baars, J. Wagstaff, and C. E. Hack. 1992. Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 24:135-148.
16. Diamond, R. D., and A. C. Allison. 1976. Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect. Immun. 14:716-720.
17. Diamond, R. D., J. E. May, M. A. Kane, M. M. Frank, and J. E. Bennett. 1974. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112:2260-2270.
18. Doebber, T. W., M. S. Wu, and T. Biftu. 1986. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes: studies with PAF receptor antagonist L-652,731. J. Immunol. 136:4659-4668.
19. Dong, Z. M., and J. W. Murphy. 1996, Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:689-698.
20. Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptacoccus neoformans antibody: study during murine cryptococcosis and mechanisms of action, J. Infect. Dis. 63:1114-1120.
21. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni, 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
22. Fox, C. L., J. M. Einbinder, and C. T. Nelson. 1958. Comparative inhibition of anaphylaxis in mice by steroids, tranquilizers and other drugs. Am. J. Physiol. 192:241-246.
23. Franks, A. K., K. I. Kujawa, and L. J. Yaffe. 1991. Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival Infect. Immun. 59:2609-2614.
24. Gadina, M., R. Bertini, M. Mengozzi, M. Zandalasini, A. Mantovani, and P. Ghezzi. 1991. Protective effect of chlerpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J. Exp. Med. 173:1305-1310.
25. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. NatL Acad. Sci. USA 76:5939-5943.
26. Gelfand, J. A., D. L. Hurley, A. S. Fauci, and M. M. Frank. 1978. Role of complement in host defense against experimental disseminated candidiasis. J. Infect. Dis. 138:9-16.
27. Henderson, D. K., J. E. Bennett, and M. A. Huber. 1982. Long-lasting, specific immunologie unresponsiveness associated with cryptococcal meningitis. J. Clin. invest. 69:1185-1190.
28. Heuer, H. O. 1991. Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170). Eur. J. Pharmacol. 199:157-163.
29. Heuer, H. O., J. Casals-Stenzel, G. Muacevic, and K. H. Weber. 1990. Pharmacologic activity of Bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J. Pharmacol. Exp. Ther. 255:962-968.
30. Heuer, H. O., G. Letts, and C. J. Meade. 1990. Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo. J. Lipid Mediators 2:S101-S108.
31. Houpt, D., G. S. T. Pfrommer, B. Young, T. Larson, and T. R. Kozel. 1994, Characteristics of antibodies in normal human serum that are reactive with the Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
32. Kozel, T. R., and J. L. Follette. 1981. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody. Infect. Immun. 31:978-984.
33. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
34. Kozel, T. R., W. F. Gulley, and J. Cazin, Jr. 1977. Immune response to Cryptococcus neofonnans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18:701-707.
35. Kozel, T. R., and C. A. Hermerath. 1988. Benzoquinone activation of Cryptococcus neoformans capsular polysaccharide for construction of an immunoaffinity column. J. Immunol. Methods 107:53-58.
36. Konzel, T. R., B. Highison, and C. H. Stratton. 1984. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect. Immun. 43:574-579.
37. Kozel, T. R., and T. G. McGaw. 1979. Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages. Infect. Immun. 25:255-261.
38. Mozaffarian, N., J. W. Herman, and A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J. Leukocyte Biol. 57:657-662.
39. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall. 1995, Protective and non-protective monoclonal antibodies to Cryptococcus neofor mans originating from one B-cell. J. Exp. Med. 181:405-409.
40. Mukherjee, J., L.-A. Pirofske, M. D. Scharff, and A. Casadevall. 1993. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:3636-3640.
41. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
42. Murphy, J. W., and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896-901.
43. Osada, S., H. Ichiki, H. Oku, K. Ishiguro, M. Kunitomo, and M. Semma. 1994. Participation of nitric oxide in mouse anaphylactic hypotension. Eur. J. Pharmacol. 252:347-350.
44. Pettoello-Mantovani, M., A. Casadevall, T. R. Kollmann, A. Rubinstein, and H. Goldstein. 1992, Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339:21-23.
45. Rao, V. S., and M. C. Fonteles. 1991. Involvement of PAF-acether and eicosanoids in adrenaline-induced pulmonary edema in mice. Braz. J. Med. Biol. Res. 24:319-321.
46. Rhodes, J. C. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23:225-234.
47. Rickert, D. E., J. Burke, and L. J. Fischer. 1975. Cyproheptadine-induced depletion of insulin in the rat J. Pharmacol. Exp. Ther. 193:585-593.
48. 2 receptor antagonist, in rodent brain. Life Sci. 54:119-127.
49. Roth, F. E., and W. M. Govier. 1958, Comparative pharmacology of chlorpheniramine (Chlor-Trimeton) and its optical isomers. J. Pharmacol. Exp. Ther. 124:347-349.
50. Sanford, J. E., D. M. Lupan, A. M. Schlageter, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919-1923.
51. Schlageter, A. M., and T. R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide- Infect. Immun. 58:1914-1918.
52. Segal, D. M. 1995. Antibody detection and preparation, p. 2.0.1-2.13.16. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology. John Wiley and Sons, Inc., New York, N.Y.
53. Steinbuch, M., and R. Audran. 1969. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch. Biochem. Biophys. 134:279-284.
54. Sun, X., W. Hsueh, and G. Torre-Amione. 1990. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury: the role of PAF and tumor necrosis factor. Am. J. Pathol. 136:949-956.
55. Szabo, C., C. C. Wu, J. A. Mitchel, S. S. Gross, C. Thiemermann, and J. R. Vane. 1993. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ, Res. 73:991-999.
56. Tarazona, R., A. Gonzalez-Garcia, N. Zamzami, P. Marchetti, N. Frechin, J. A. Gonzalo, M. Ruiz-Gayo, N. van Rooijen, C. Martinez-A., and G. Kroemer. 1995. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J. Immunol. 154:861-870.
57. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey III, A. Zentella, J. D. Albert, G. T. Shires, and A. Cerami. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474.
58. van Rooijen, N. 1989. The liposome-mediated macrophage "suicide' technique. J. Immunol. Methods 124:1-6.
59. van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174:83-93.
60. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Crypiococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:2846-2849.
61. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect. Immun. 63:2919-2923.
62. Wlaz, P., Z. Rolinski, Z. Kleinrok, and S. J. Czuczwar 1993. Influence of chronic aminophylline on the anticonvulsant efficacy of phenobarbital and valproate in mice. Epilepsia 34:385-389.
63. Yushmanov, V. E., D. S. Khristianovich, T. V. Rozantseva, and L. A. Sibeldina. 1996. NMR estimation of protective effect of insulin on mouse liver with epinephrine-induced metabolic lesions. NMR Biomed. 4:167-172.